A Phase 2/3 interventional study of RO7239361 and Placebo for RO7239361 in Duchenne Muscular Dystrophy, sponsored by Hoffmann-La Roche. Completed at 44 sites in 13 countries. Open to male participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-12-21.
Sponsored by Hoffmann-La Roche · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 17th largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2017, is one of 8 in phase 2/3, and was the 112th registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 11 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 90 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 171 interventional studies, 75 across the 55 observational. Of the 160 that completed or were terminated, 78 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 232 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 3 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
20 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT03368742Solid Biosciences Inc.Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | 2026-11-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined Inclusion/Exclusion Criteria could apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received low dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received low dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
Drug: RO7239361
Participants received high dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
Drug: RO7239361
Participants received matching placebo solution subcutaneously (SC) on specified days of the 48-week double-blind (DB) period. Following the DB period participants received low dose or high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
Drug: Placebo for RO7239361
Take RO7239361 subcutaneously on specified days over a 48 week blinded period
Take placebo subcutaneously on specified days over a 48 week blinded period
Baseline for the North Star Ambulatory Assessment (NSAA) Total Score
The NSAA is a functional scale specifically designed for ambulant boys with Duchenne muscular dystrophy (DMD) that can provide information about motor function. The NSAA is a 17-item test of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0-2: 0 = unable to achieve independently, 1 = modified method but achieves goal independent of physical assistance from another, or 2 = normal with no obvious modification of activity. Total score range is 0 to 34. Higher scores reflect better performance.
Time frame: Baseline
Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 48
The NSAA is a functional scale specifically designed for ambulant boys with Duchenne muscular dystrophy (DMD) that can provide information about motor function. The NSAA is a 17-item test of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0-2: 0 = unable to achieve independently, 1 = modified method but achieves goal independent of physical assistance from another, or 2 = normal with no obvious modification of activity. Total score range is 0 to 34. Higher scores reflect better performance. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
Time frame: Baseline, Week 48
Baseline Time for 4 Stair Climb
The time to complete the 4 stair climb was measured at baseline.
Time frame: Baseline
Change From Baseline at Week 48 in 4 Stair Climb Velocity (4SCV)
4SCV was calculated as the ratio of the number of stairs climbed (4) divided by the number of seconds taken to complete the 4-stair climb. The results were converted into velocity (distance/time). A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
Time frame: Baseline, Week 48
Baseline for the Time to Stand From Supine
The time required for a participant to stand from supine position. A longer time reflects a worse outcome.
Time frame: Baseline
Change From Baseline at Week 48 in Stand From Supine Velocity
The time required for a participant to stand from supine position. A longer time reflects a worse outcome. A negative change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
Time frame: Baseline, Week 48
Baseline Time for 10 Meter Walk/Run
The time required for a participant to run or walk a distance of 10 meters as quickly as possible. A longer time reflects a worse outcome.
Time frame: Baseline
Change From Baseline at Week 48 in 10 M Walk/Run Velocity
The time required for a participant to run or walk a distance of 10 meters as quickly as possible calculated as velocity (distance/time). A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
Time frame: Baseline, Week 48
Baseline for the Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale
The PODCI is designed to be completed by the parent/guardian of a child who has knowledge of the child's conditions. The Transfer and Basic Mobility scale is one of the subscales of the PODCI. The results are standardized into a scale of 0-100 with a higher score reflecting better performance.
Time frame: Baseline
Change From Baseline at Week 48 in Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale
The PODCI is designed to be completed by the parent/guardian of a child who has knowledge of the child's conditions. The Transfer and Basic Mobility scale is one of the subscales of the PODCI. The results are standardized into a scale of 0-100 with a higher score reflecting better performance. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
Time frame: Baseline, Week 48
Change From Baseline at Week 48 in Proximal Lower Extremity Flexor Strength
Proximal lower extremity flexor (knee extension and knee flexion) strength was measured using manual myometry. A higher score reflects a better outcome. A positive change from baseline indicates an improvement.
Time frame: Baseline, Week 48
Baseline for the 6 Minute Walk Distance (6MWD)
The 6MWD measured the distance a participant was able to traverse while walking for 6 minutes. A longer distance reflects a better outcome.
Time frame: Baseline
Change From Baseline at Week 48 in 6 Minute Walk Distance (6MWD)
The 6MWD measured the distance a participant was able to traverse while walking for 6 minutes. A longer distance reflects a better outcome. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
Time frame: Baseline, Week 48
Percentage of Participants for Each Clinical Global Impression of Change (CGI-C) Assessment Status at Week 48
The CGI-C was used to assess the participant's overall condition on a 7-point scale, using the status markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse" at Week 48 as compared to baseline.
Time frame: Baseline, Week 48
Change From Baseline at Week 48 in 95th Percentile Stride Velocity
Stride velocity was recorded with the ActiMyo device in a subset of the overall study population. The ActiMyo device measures the daily movement and activity levels of the participant. The device consists of two sensors worn on each ankle. A higher velocity reflects a better outcome. A positive change from baseline indicates an improvement.
Time frame: Baseline, Week 48
Number of Participants With Adverse Events (AEs)
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: During DB period (48 weeks) and Whole study (up to approximately 34 months)
Number of Participants With AEs Leading to Discontinuation
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Reported here is the number of participants with AEs that led to study discontinuation.
Time frame: During DB period (48 weeks) and Whole study (up to approximately 34 months)
| Milestone | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Started | 56 | 55 | 55 |
| Completed | 29 | 26 | 32 |
| Not completed | 27 | 29 | 23 |
| Withdrew: Administrative reason by sponsor | 24 | 25 | 21 |
| Withdrew: Subject request to discontinue study treatment | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
| Milestone | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Started | 0 | 38 | 42 |
| Completed db, did not start ol | 2 | 2 | 3 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 38 | 42 |
| Withdrew: Administrative reason by sponsor | 0 | 34 | 41 |
| Withdrew: Subject request to discontinue study treatment | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 1 |
The NSAA is a functional scale specifically designed for ambulant boys with Duchenne muscular dystrophy (DMD) that can provide information about motor function. The NSAA is a 17-item test of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0-2: 0 = unable to achieve independently, 1 = modified method but achieves goal independent of physical assistance from another, or 2 = normal with no obvious modification of activity. Total score range is 0 to 34. Higher scores reflect better performance.
| score on a scale | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Baseline for the North Star Ambulatory Assessment (NSAA) Total Score | 23.1 ± 6.4 | 24.5 ± 5.5 | 22.7 ± 6.7 |
The NSAA is a functional scale specifically designed for ambulant boys with Duchenne muscular dystrophy (DMD) that can provide information about motor function. The NSAA is a 17-item test of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0-2: 0 = unable to achieve independently, 1 = modified method but achieves goal independent of physical assistance from another, or 2 = normal with no obvious modification of activity. Total score range is 0 to 34. Higher scores reflect better performance. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
| score on a scale | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 48 | -2.99 ± 0.65 | -3.44 ± 0.67 | -2.41 ± 0.64 |
The time to complete the 4 stair climb was measured at baseline.
| seconds (secs) | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Baseline Time for 4 Stair Climb | 3.81 ± 1.55 | 3.85 ± 1.61 | 3.92 ± 1.91 |
4SCV was calculated as the ratio of the number of stairs climbed (4) divided by the number of seconds taken to complete the 4-stair climb. The results were converted into velocity (distance/time). A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
| stairs/sec | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Change From Baseline at Week 48 in 4 Stair Climb Velocity (4SCV) | -0.15 ± 0.07 | -0.15 ± 0.07 | -0.07 ± 0.07 |
The time required for a participant to stand from supine position. A longer time reflects a worse outcome.
| secs | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Baseline for the Time to Stand From Supine | 6.28 ± 4.75 | 6.15 ± 4.07 | 7.24 ± 9.22 |
The time required for a participant to stand from supine position. A longer time reflects a worse outcome. A negative change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
| 1/sec | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Change From Baseline at Week 48 in Stand From Supine Velocity | -0.05 ± 0.01 | -0.02 ± 0.01 | -0.02 ± 0.01 |
The time required for a participant to run or walk a distance of 10 meters as quickly as possible. A longer time reflects a worse outcome.
| secs | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Baseline Time for 10 Meter Walk/Run | 5.38 ± 1.48 | 5.51 ± 1.68 | 5.68 ± 2.30 |
The time required for a participant to run or walk a distance of 10 meters as quickly as possible calculated as velocity (distance/time). A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
| m/sec | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Change From Baseline at Week 48 in 10 M Walk/Run Velocity | -0.23 ± 0.06 | -0.14 ± 0.07 | -0.23 ± 0.06 |
The PODCI is designed to be completed by the parent/guardian of a child who has knowledge of the child's conditions. The Transfer and Basic Mobility scale is one of the subscales of the PODCI. The results are standardized into a scale of 0-100 with a higher score reflecting better performance.
| score on a scale | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Baseline for the Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale | 85.59 ± 10.21 | 86.54 ± 9.52 | 84.47 ± 14.76 |
The PODCI is designed to be completed by the parent/guardian of a child who has knowledge of the child's conditions. The Transfer and Basic Mobility scale is one of the subscales of the PODCI. The results are standardized into a scale of 0-100 with a higher score reflecting better performance. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
| score on a scale | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Change From Baseline at Week 48 in Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale | -5.47 ± 1.79 | -7.47 ± 1.83 | -4.51 ± 1.77 |
Proximal lower extremity flexor (knee extension and knee flexion) strength was measured using manual myometry. A higher score reflects a better outcome. A positive change from baseline indicates an improvement.
| kilogram (kg) | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Baseline: Knee Extenders | 5.58 ± 2.87 | 6.25 ± 3.63 | 5.76 ± 3.53 |
| Change from Baseline at Week 48: Knee Extenders | -1.19 ± 2.13 | -0.47 ± 2.43 | -0.88 ± 2.97 |
| Baseline: Knee Flexors | 5.04 ± 2.58 | 5.70 ± 3.08 | 5.04 ± 2.72 |
| Change from Baseline at Week 48: Knee Flexors | 0.15 ± 2.24 | 0.08 ± 2.53 | -0.13 ± 2.29 |
The 6MWD measured the distance a participant was able to traverse while walking for 6 minutes. A longer distance reflects a better outcome.
| meters (m) | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Baseline for the 6 Minute Walk Distance (6MWD) | 388.33 ± 69.59 | 399.73 ± 68.35 | 370.73 ± 93.35 |
The 6MWD measured the distance a participant was able to traverse while walking for 6 minutes. A longer distance reflects a better outcome. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).
| meters (m) | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Change From Baseline at Week 48 in 6 Minute Walk Distance (6MWD) | -41.3 ± 8.7 | -39.6 ± 9.0 | -30.0 ± 8.7 |
The CGI-C was used to assess the participant's overall condition on a 7-point scale, using the status markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse" at Week 48 as compared to baseline.
| percentage of participants | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Very much improved | 0 | 0 | 0 |
| Much improved | 5.6 | 2.7 | 3.2 |
| Minimally improved | 13.9 | 13.5 | 19.4 |
| No change | 58.3 | 54.1 | 51.6 |
| Minimally worse | 16.7 | 18.9 | 22.6 |
| Much worse | 5.6 | 10.8 | 3.2 |
| Very much worse | 0 | 0 | 0 |
Stride velocity was recorded with the ActiMyo device in a subset of the overall study population. The ActiMyo device measures the daily movement and activity levels of the participant. The device consists of two sensors worn on each ankle. A higher velocity reflects a better outcome. A positive change from baseline indicates an improvement.
| m/sec | Placebo | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|
| Baseline | 1.69 ± 0.33 | 1.54 ± 0.35 | 1.57 ± 0.46 |
| Change from Baseline at Week 48 | -0.25 ± 0.39 | -0.22 ± 0.22 | -0.28 ± 0.29 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| participants | Placebo DB | RO7239361 Low Dose DB | RO7239361 High Dose DB | RO7239361 Low Dose | RO7239361 High Dose Whole Study |
|---|---|---|---|---|---|
| Double-Blind Period | 46 | 48 | 49 | — | — |
| Whole Study | — | — | — | 57 | 56 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Reported here is the number of participants with AEs that led to study discontinuation.
| participants | Placebo DB | RO7239361 Low Dose DB | RO7239361 High Dose DB | RO7239361 Low Dose | RO7239361 High Dose |
|---|---|---|---|---|---|
| Double-Blind Period | 0 | 0 | 0 | — | — |
| Whole Study | — | — | — | 0 | 0 |
Collected over Up to approximately 34 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo DB | 0/56 (0%) | 3/56 (5.4%) | 43/56 (76.8%) |
| RO7239361 Low Dose DB | 0/55 (0%) | 2/55 (3.6%) | 43/55 (78.2%) |
| RO7239361 High Dose DB | 1/55 (1.8%) | 4/55 (7.3%) | 47/55 (85.5%) |
| Placebo, Then RO7239361 Low Dose OL | 0/14 (0%) | 0/14 (0%) | 8/14 (57.1%) |
| Placebo, Then RO7239361 High Dose OL | 0/13 (0%) | 0/13 (0%) | 7/13 (53.8%) |
| RO7239361 Low Dose, Then RO7239361 Low Dose OL | 0/24 (0%) | 0/24 (0%) | 13/24 (54.2%) |
| RO7239361 High Dose, Then RO7239361 High Dose OL | 0/29 (0%) | 0/29 (0%) | 12/29 (41.4%) |
| Event | Placebo DB | RO7239361 Low Dose DB | RO7239361 High Dose DB | Placebo, Then RO7239361 Low Dose OL | Placebo, Then RO7239361 High Dose OL | RO7239361 Low Dose, Then RO7239361 Low Dose OL | RO7239361 High Dose, Then RO7239361 High Dose OL |
|---|---|---|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 0/56 | 0/55 | 1/55 | 0/14 | 0/13 | 0/24 | 0/29 |
| Supraventricular tachycardiaCardiac disorders | 0/56 | 0/55 | 1/55 | 0/14 | 0/13 | 0/24 | 0/29 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/56 | 0/55 | 1/55 | 0/14 | 0/13 | 0/24 | 0/29 |
| Viral infectionInfections and infestations | 0/56 | 1/55 | 0/55 | 0/14 | 0/13 | 0/24 | 0/29 |
| Humerus fractureInjury, poisoning and procedural complications | 0/56 | 1/55 | 0/55 | 0/14 | 0/13 | 0/24 | 0/29 |
| OverdoseInjury, poisoning and procedural complications | 0/56 | 0/55 | 1/55 | 0/14 | 0/13 | 0/24 | 0/29 |
| MyocarditisCardiac disorders | 1/56 | 0/55 | 0/55 | 0/14 | 0/13 | 0/24 | 0/29 |
| Influenza like illnessGeneral disorders | 1/56 | 0/55 | 0/55 | 0/14 | 0/13 | 0/24 | 0/29 |
| Gastrointestinal viral infectionInfections and infestations | 1/56 | 0/55 | 0/55 | 0/14 | 0/13 | 0/24 | 0/29 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/56 | 0/55 | 0/55 | 0/14 | 0/13 | 0/24 | 0/29 |
| Event | Placebo DB | RO7239361 Low Dose DB | RO7239361 High Dose DB | Placebo, Then RO7239361 Low Dose OL | Placebo, Then RO7239361 High Dose OL | RO7239361 Low Dose, Then RO7239361 Low Dose OL | RO7239361 High Dose, Then RO7239361 High Dose OL |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 9/56 | 14/55 | 10/55 | 1/14 | 0/13 | 2/24 | 2/29 |
| NasopharyngitisInfections and infestations | 13/56 | 13/55 | 13/55 | 2/14 | 0/13 | 0/24 | 2/29 |
| Injection site erythemaGeneral disorders | 8/56 | 11/55 | 12/55 | 0/14 | 3/13 | 2/24 | 1/29 |
| DiarrhoeaGastrointestinal disorders | 3/56 | 10/55 | 4/55 | 0/14 | 0/13 | 1/24 | 2/29 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/56 | 8/55 | 7/55 | 1/14 | 0/13 | 0/24 | 1/29 |
| PyrexiaGeneral disorders | 8/56 | 9/55 | 8/55 | 2/14 | 1/13 | 3/24 | 1/29 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/56 | 2/55 | 2/55 | 1/14 | 2/13 | 0/24 | 1/29 |
| VomitingGastrointestinal disorders | 6/56 | 8/55 | 6/55 | 0/14 | 0/13 | 3/24 | 2/29 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/56 | 4/55 | 8/55 | 1/14 | 0/13 | 0/24 | 0/29 |
| Ligament sprainInjury, poisoning and procedural complications | 4/56 | 1/55 | 1/55 | 2/14 | 0/13 | 3/24 | 1/29 |
| Age, Continuous(years) | Placebo | RO7239361 Low Dose | RO7239361 High Dose | Total |
|---|---|---|---|---|
| Mean | 8.4 ± 1.7 | 8.5 ± 1.8 | 8.4 ± 1.5 | 8.5 ± 1.7 |
| Age, Customized(participants) | Placebo | RO7239361 Low Dose | RO7239361 High Dose | Total |
|---|---|---|---|---|
| Children (6-11 years) | 56 | 55 | 55 | 166 |
| Sex: Female, Male(Participants) | Placebo | RO7239361 Low Dose | RO7239361 High Dose | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 56 | 55 | 55 | 166 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | RO7239361 Low Dose | RO7239361 High Dose | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 5 | 6 | 18 |
| Not Hispanic or Latino | 43 | 41 | 43 | 127 |
| Unknown or Not Reported | 6 | 9 | 6 | 21 |
| Race/Ethnicity, Customized(participants) | Placebo | RO7239361 Low Dose | RO7239361 High Dose | Total |
|---|---|---|---|---|
| Asian | 9 | 7 | 7 | 23 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 1 | 1 |
| White | 42 | 45 | 45 | 132 |
| Other | 5 | 3 | 2 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Apr 2020, 33 months.
Results were first posted in Dec 2020, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Taldefgrobep alfa
Muscular Dystrophy, Duchenne →